Manufacturing biologics is a much more involved and complicated process than the chemical synthesis required for small molecule drugs. As a result, some sponsors are unlikely to outsource the process because of its complexity. Others are more likely to outsource bioprocessing because they need access to scientific expertise not possessed in-house. ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report affords readers the opportunity to gain insight into the bioprocessing market and where it’s heading. This report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what our survey respondents predict the marketplace will look like in five years. The report also explores the types of biologics sponsor organizations currently have in development and on the market and the likelihood of outsourcing a bioprocessing project by the type of biologic. Learn more: https://goo.gl/q18W3C

1. BIOPROCESSING
MARKET TRENDS
AND OUTSOURCING
DYNAMICS:
2016-2021
A P R I L , 2 0 1 6
P R E V I E W O F

2. REPORT OVERVIEW
HOW YOU CAN USE THIS REPORT
D A T A
C O L L E C T I O N
I N Q 1 , 2 0 1 6
3 0 - M I N U T E
W E B - B A S E D
S U R V E Y
79
PAGES
75
CHARTS
AND GRAPHS
VALUABLE FOR
MAJOR
SECTIONS:
1. Bioprocessing Market
Dynamics
2. Service Provider
Perceptions and Selection
3. Trends, Predictions and
Preferences
4. Study Data
Introduction
SMARTER QUESTIONS SMARTER ANSWERS
Full table of contents
included on next page.
DRUG DEVELOPERS
• Gain insight into where the biologics industry is heading over
the next five years with respect to protein expression systems
utilized and types of biologics in development
• Understand the CMO usage patterns of industry peers to
identify whether additional outsourcing advatanges can be
obtained for your organization
• Learn the criteria used by peers to select bioprocessing contract
manufacturers that help to scientifically and strategically
evaluate service providers for bioprocessing projects
CONTRACT MANUFACTURERS
• Pinpoint which CMO attributes have led to successful
outsourcing relationships, those that have caused service
providers to lose bids and what truly drives sponsor
satisfaction, then internally assess your company on these
metrics
• Identify changes in demand for outsourced activities and
services in order to prepare for future needs
• Better position your company to win business by
understanding the dynamics of different buyer groups (by
sponsor company type and geography) and developing
targeted marketing to speak directly to their unique needs
PHARMA/BIOTECH
OUTSOURCING
CMO MARKETING
BUSINESS DEVELOPMENT
EXECUTIVE MANAGEMENT
OPERATIONS
Manufacturing biologics is a much more involved and
complicated process than the chemical synthesis required
for small molecule drugs. As a result, some sponsors are
unlikely to outsource the process because of its complexity.
Others are more likely to outsource bioprocessing because
they need access to scientific expertise not possessed in-
house.
ISR’s Bioprocessing Market Trends and Outsourcing
Dynamics: 2016-2021 report affords readers the opportunity
to gain insight into the bioprocessing market and where it’s
heading. This report provides an overview of the current
market dynamics for bioprocessing as well as an outlook
on what our survey respondents predict the marketplace
will look like in five years. The report also explores the
types of biologics sponsor organizations currently have
in development and on the market and the likelihood of
outsourcing a bioprocessing project by the type of biologic.
1 0 0 R E S P O N D E N T S
F R O M N O R T H
A M E R I C A , E U R O P E ,
A N D A S I A

3. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
STUDY FINDINGS
10www.ISRreports.com ©2016 Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021
Bioprocessing Project & CMO Volume
The average number of bioprocessing projects per year skews high at 14�4 due to the substantial
proportion of respondents from large biopharma companies, where an average of 20�4 bioprocessing
projects per year are conducted� More than half of all bioprocessing projects are outsourced, and an
average of 5�7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs�
Large biopharma companies use an average of 7�1 CMOs, more than twice as many as non-large
companies require to meet their outsourced bioprocessing needs (3�1)� Non-large biopharma
outsources a much higher proportion of their bioprocessing than large biopharma (74% vs 48%), which
relates back to non-large biopharmaceutical companies using CMOs for all of their manufacturing
needs�
Respondents who work for biopharmaceutical companies headquartered in Europe averaged more
bioprocessing projects per year than their North American counterparts� While outsourcing rates are
similar (54% Europe vs 58% North America), European biopharmas require fewer CMOs on average (4�2
vs 6�5)�
“About how many bioprocessing projects (both in-house and outsourced) would you estimate your
company conducts on average per year?” (Base=100)
“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best
estimate is fine. Responses must be between 0% and 100%.” (Base=100)
“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)
4.2
6.5
3.1
7.1
5.7
54%
58%
74%
48%
57%
18.2
13.0
3.3
20.4
14.4
0 10 20 30 40 50 60 70 80
Western Europe (n=31)
North America (n=67)
Non-large Biopharma - R&D <$1B (N=36)
Large Biopharma - R&D $1B+ (n=64)
Overall (n=100)
# of Projects / % Outsourced / # of CMOs
Average # of Projects
% Outsourced
Average # of CMOs
© Industry Standard Research
S A M P L E P A G E :
BIOPROCESSING
PROJECT & CMO
VOLUME
ISR surveyed 100 respondents at
pharma and biotech companies.
The Bioprocessing Market
Dynamics section of this report
includes data regarding current
outsourcing volume, types
of biologics outsourced, and
predictions for future trends in the
market.
This page details the average
number of bioprocessing
projects at each company, the
percentage of these projects that
are outsourced, and the average
number of CMOs each company
works with on bioprocessing
projects.
Full data is available in the report.
C L O S E R L O O K
Understanding project
volume and the degree
to which bioprocessing
is outsourced helps both
drug developers and
CMOs make strategic
decisions.
Learn more in the full
report:
www.ISRreports.com
STUDY FINDINGS
Bioprocessing Project & CMO Volume
The average number of bioprocessing projects per year skews high at 14�4 due to the substantial
proportion of respondents from large biopharma companies, where an average of 20�4 bioprocessing
projects per year are conducted� More than half of all bioprocessing projects are outsourced, and an
average of 5�7 contract manufacturers are engaged to fulfill sponsor companies’ bioprocessing needs�
Large biopharma companies use an average of 7�1 CMOs, more than twice as many as non-large
companies require to meet their outsourced bioprocessing needs (3�1)� Non-large biopharma
outsources a much higher proportion of their bioprocessing than large biopharma (74% vs 48%), which
relates back to non-large biopharmaceutical companies using CMOs for all of their manufacturing
needs�
Respondents who work for biopharmaceutical companies headquartered in Europe averaged more
bioprocessing projects per year than their North American counterparts� While outsourcing rates are
similar (54% Europe vs 58% North America), European biopharmas require fewer CMOs on average (4�2
vs 6�5)�
“About how many bioprocessing projects (both in-house and outsourced) would you estimate your
company conducts on average per year?” (Base=100)
“Overall, what proportion of your organization’s bioprocessing is currently outsourced? Your best
estimate is fine. Responses must be between 0% and 100%.” (Base=100)
“How many CMOs does your company work with to meet its bioprocessing needs?” (Base=100)
4.2
6.5
3.1
7.1
5.7
54%
58%
74%
48%
57%
18.2
13.0
3.3
20.4
14.4
0 10 20 30 40 50 60 70 80
Western Europe (n=31)
North America (n=67)
Non-large Biopharma - R&D <$1B (N=36)
Large Biopharma - R&D $1B+ (n=64)
Overall (n=100)
# of Projects / % Outsourced / # of CMOs
Average # of Projects
% Outsourced
Average # of CMOs
© Industry Standard Research
The average number of bioprocessing projects per year skews high at 14.4 due to the
substantial proportion of respondents from large biopharma companies, where an average
of 20.4 bioprocessing projects per year are conducted. More than half of all bioprocessing
projects are outsourced, and an average of 5.7 contract manufacturers are engaged to
fulfill sponsor companies’ bioprocessing needs.
“About how many bioprocessing projects (both in-house and outsourced) would you
estimate your company conducts on average per year?” (Base=100)
“Overall, what proportion of your organization’s bioprocessing is currently outsourced?
Your best estimate is fine. Responses must be between 0% and 100%.” (Base=100)
“How many CMOs does your company work with to meet its bioprocessing needs?”
(Base=100)
D A T A I N F U L L R E P O R T
D A T A I N F U L L R E P O R T

4. Introduction
SMARTER QUESTIONS SMARTER ANSWERS
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services
industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at
www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
ABOUT INDUSTRY STANDARD RESEARCH
>> R E G I S T E R N O W
>>Receive $250 instant credit towards any ISR report
>>Earn 10% credit towards all future purchases
>>Receive advanced notifications on ISR’s latest reports and
free resources
SAVE ON THIS,
OR ANY ISR REPORT, BY
CREATING A
FREE ACCOUNT
MORE INFORMATION
To get more information about this report, including the full table of contents,
sample pages, and pricing, please download the full preview from ISR’s website:
https://www.isrreports.com/reports/bioprocessing-market-trends-and-
outsourcing-dynamics-2016-2021/

5. TO LEARN MORE: CONTACT US AT INFO@ISRREPORTS.COM OR +1(919)301-0106
Biosimilars &
Biologics
Clinical Trial
Recruitment &
Retention
Commercialization Department
Models &
Structures
Trends &
Technologies
Manufacturing Service
Provider Quality
Benchmarking
CUSTOM RESEARCH
UNDERSTAND YOUR MARKETS
Leverage ISR’s experience and institutional
knowledge to create a fit-for-purpose market
research project that addresses the business
decisions you need to make.
Are you:
• Developing a new product or service?
• Evaluating a new market?
• Targeting a new customer segment?
• Entering a new geography?
• Needing a deeper understanding of your
customer or potential customer base?
UNDERSTAND YOUR CUSTOMERS
Who makes the decisions and in what contexts?
ISR can help you gain a deeper understanding of
your customers’ decision-making units (DMUs) and
decision-making processes (DMPs).
Key Questions Addressed:
• What motivates the purchase decision?
• How are companies, products, solutions, and/or
brands evaluated?
• What factors drive the final buying decision?
• Where are your customers won or lost in the
purchasing process?
• Why were specific opportunities won or lost?
• How do you keep customers engaged and
manage their loyalty over time?
CUSTOM RESEARCH SERVICES
• Investigator Forum
• Brand, Advertising, and Message Testing
• Loyalty Management
• New Product and Service Development
• Competitive Intelligence
• Strategy War Games
• MORE
S O M E T H I N G T O C O N S I D E R
DISTINCTIVE – Receive novel insights
from industry decision-makers on topics
including: service provider quality, patient
recruitment, biosimilars, clinical technology,
manufacturing, clinical operations, and
commercial activities.
UNRESTRICTED – ISR doesn’t sell seats.
Instantly obtain access for all employees within
your organization
AFFORDABLE – Receive access to
ALL reports in ISR’s library, as well as those
released during your subscription period. ISR’s
competitive library pricing equates to the cost of
a few individual report purchases.
LIBRARY ACCESS
SUBSCRIPTION
ISR’s library access subscription provides your entire
organization access to our full library of syndicated
market research reports (100+ titles) plus access
to all reports (~25 per year) released during your
subscription period.
Our research categories include:

6. THE ISR DIFFERENCE
Mostly primary
research; always
appropriate for
the topic
One size
fits all; usually
publically
available data
To learn more, visit www.ISRreports.com
ISR’S
REPORTS
THE
COMMON
SYNDICATED
REPORT
VS.
RESEARCH METHODS
ISR’s proprietary data
tools and channels
support fast, high
quality data collection
Struggle to
recurit the right
targets and
enough of them
DATA COLLECTION
Sophisticated screening
ensures genuine
decision-makers
make up respondents
Undisclosed
methodologies
and respondent
demographics
RESPONDENTS
Robust
sample sizes
that instill
confidence
Often insufficient
industry representation
that leaves you
defending results
SAMPLE SIZE
Decades of experience
means more
insights that are
immediately usable
Junior analysts
capable of
reporting
numbers
ANALYSTS
ISR’S HEALTH PANEL
The industry’s fastest growing panel
of health care and pharmaceutical
professionals, with nearly 1,500
members worldwide.
BY
JOB
LEVEL
Director 46%
Manager
29%
C-level 13%
VP 10%
BY
EXPERIENCE
IN YEARS
16-20 years 23%
11-15
years
24%
6-10 years 11%
3-5 years 5%
20+
years
37%
BY
COMPANY
TYPE
Other 6%
Sponsor 78%
CRO 6%
Research
Site 10%